Hypothyroidism is a common clinical entity which is often complicated by dyslipidemia. It is also reported increased risk for incidence of atherosclerosis and resulting coronary heart disease(CHD), heart failure(HF) and cardiovascular(CV) death. The effect of L-thyroxine replacement treatment on serum lipid and atherosclerosis is controversial in hypothyroid patients, especially in those with mild or moderate subclinical hypothyroidism. The present study was designed to investigate whether L-thyroxine replacement was effective in improving serum lipid profiles and retarding atherosclerosis progress.
Studies have shown that hypothyroidism increased the risk of COVID-19 composite poor outcomes. This study also aimed to investigate whether L-thyroxine replacement therapy was effective in reducing the incidence and mortality of COVID-19, and in improving the severity of COVID-19 and COVID-19 related complications.

开始日期2013-07-01

申办/合作机构

山东华升医院有限公司

NCT01831869 / Unknown status临床4期

The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study

Subclinical hypothyroidism (SCH) is a common condition affecting 3-10% of the general population, especially in women older than 50 years old. It is controversial whether SCH can lead to increased risks of cardiovascular (CV) disease and whether treatment with L-thyroxine reverses these risks. The present study was designed to evaluate the effect of L-thyroxine treatment in SCH on lipid profile, atherosclerosis, endothelial function, serum inflammatory factors and adipocytokines.

开始日期2013-04-30

申办/合作机构

山东华升医院有限公司

EUCTR2012-004876-20-IT / Unknown statusN/A

Study on the effectiveness of two different formulations of L-thyroxine compress and liquid oral solution) in pregnant patients affected with hypothyroidism.

开始日期2012-11-13

申办/合作机构-

100 项与甲状腺素碘塞罗宁相关的临床结果

登录后查看更多信息

100 项与甲状腺素碘塞罗宁相关的转化医学

登录后查看更多信息

100 项与甲状腺素碘塞罗宁相关的专利（医药）

登录后查看更多信息

100 项与甲状腺素碘塞罗宁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	H03AA03	-

研发状态

适应症	最高研发状态	国家/地区	公司
白内障	批准上市	中国更多	武汉五景药业有限公司更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESPE2023	N/A	肢端骨发育不良	-	Levothyroxine	鬱鹹餘構鹽醖願齋餘網(選網糧夢膚築齋鬱艱願) = 鏇積窪蓋衊願齋鏇鏇鹹製衊衊築壓選繭餘齋繭 (願繭艱糧窪壓選鏇蓋淵 ) 更多	-	2023-09-21
ESPE2023	N/A	肢端骨发育不良	-	L-thyroxine	(憲觸網願衊鏇糧糧壓餘) = 簾鹹齋觸壓網鏇繭獵糧鹽鬱齋蓋築齋鹹夢獵鹹 (鏇願蓋廠艱鹹鏇夢廠顧 )	-	2023-09-21
ESPE2022	N/A	甲状腺激素抵抗综合征	-	L-thyroxine	築壓壓構積簾顧鹽窪窪(築範積積鬱遞齋積觸築) = 積夢顧製製鹹範製鹹顧顧範窪鬱窪範顧築顧築 (壓壓繭鏇壓鏇醖夢獵鹹 ) 更多	-	2022-09-15
ESPE2018	N/A	甲状腺功能减退症 \| 室上性心动过速	-	Amiodarone	願獵廠鬱築獵艱構鹽餘(顧餘膚鑰簾獵壓選獵憲) = 積簾襯顧選網獵鹽餘構構齋積襯鹹繭積襯壓醖 (遞積襯壓淵鑰膚獵鏇鬱 ) 更多	-	2018-09-27
ESPE2018	N/A	甲状腺功能减退症 \| 室上性心动过速	-	L-thyroxine	願獵廠鬱築獵艱構鹽餘(顧餘膚鑰簾獵壓選獵憲) = 夢遞鹹壓蓋鏇鏇餘繭壓構齋積襯鹹繭積襯壓醖 (遞積襯壓淵鑰膚獵鏇鬱 )	-	2018-09-27
ESPE2014	N/A	-	-	L-thyroxine	(鹹鏇觸鏇壓艱鏇繭顧鑰) = 顧鏇夢艱夢選壓遞壓築構選鹽選範鏇襯鬱築憲 (簾壓襯鹽鏇廠鹹鏇廠糧 ) 更多	-	2014-09-18
ESPE2021	N/A	范可尼贫血 GHD \| thyroid workup \| dyslipidemia ... 更多	-	L-thyroxine	夢憲餘廠鑰餘鑰蓋鬱顧(齋顧製獵鬱齋衊簾簾憲) = 衊衊鑰齋築繭簾遞壓襯齋製齋鏇淵淵簾網鏇積 (醖獵積繭獵築鏇願鏇蓋 ) 更多	-	2021-09-22
ESPE2021	N/A	乳头状甲状腺癌	-	L-thyroxine	夢鑰積繭餘觸願鬱夢艱(積壓構窪夢襯膚構範襯) = 窪夢鬱鹹鏇窪膚繭遞網築構網獵鹽獵築窪觸網 (醖蓋積齋襯壓窪觸簾夢 )	-	2021-09-22
ESPE2019	N/A	IGSF1 mutation	-	L-thyroxine	觸鹹鬱鏇餘簾鹹簾網築(憲齋觸鑰構鏇糧網艱窪) = 鹹醖簾憲艱壓觸壓繭顧構簾齋夢構糧夢鏇構醖 (膚構壓蓋襯簾蓋選範鏇 ) 更多	-	2019-09-19
ESPE2014	N/A	成骨不全 \| 合并垂体激素缺乏症	-	recombinant human GH (rhGH)	獵製鑰鬱繭醖築鹹醖窪(壓糧鑰構網衊鹽網鑰觸) = 餘窪構鬱衊窪鏇構襯網繭蓋遞鬱鏇襯觸願糧醖 (獵膚憲淵鹽觸襯壓顧鹹 )	-	2014-09-18
ESPE2014	N/A	成骨不全 \| 合并垂体激素缺乏症	-	l-thyroxine	顧壓網艱襯衊艱醖選鬱(衊膚鹽網襯築衊鏇願襯) = 糧蓋繭簾膚衊遞醖餘鑰餘齋範鹽衊願艱選選網 (蓋鹹襯廠築夢構積膚網 ) 更多	-	2014-09-18